PAT for the On-line Characterization of Continuous Manufacturing Systems
|
|
- Octavia Dixon
- 5 years ago
- Views:
Transcription
1 PAT for the On-line Characterization of Continuous Manufacturing Systems Thomas O Connor, Ph.D. Office of Pharmaceutical Science FDA/PQRI Conference: Innovation in Manufacturing and Regulatory Assessment September 16 th,
2 2 Disclaimer This presentation reflects the views of the author and should not be construed to represent FDA s views or policies
3 3 Objectives and Outline Objectives To delineate why PAT is critical for the monitoring and control of a continuous process To illustrate the role of process monitoring in the control strategy for a continuous process and the advantages of multivariate tools Outline Role of PAT for Continuous Manufacturing Process Monitoring and Control Multivariate Statistical Process Control (MSPC) Considerations for the Implementation of MSPC Concluding Remarks
4 4 Process Analytical Technology Process analytical technology (PAT) is a system for designing, analyzing, and controlling manufacturing through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes, with the goal of ensuring final product quality PAT Guidance PAT tools Multivariate tools for design, data acquisition, and analysis Process analyzers Process control tools Continuous improvement and knowledge management tools
5 A Conceptual Example of Control Strategy in Continuous Manufacturing Receiving Feeder Granulation Blending Drying Milling At-line Chemical Properties & Physical Properties for Raw Materials Concentration & Uniformity (Multi-component) Chemometric model Feed Frame Tablet Press Online Assay Chemometric model Weight & Hardness Coating Blending Digital Imaging Surrogate Dissolution Model (release) Raw material characterization, process data, & chemometric model outputs integrated into a supervisory control and data acquisition (SCADA) system Particle size distribution Moisture content Real-Time Release Testing 5
6 Role of PAT for Continuous Processes Necessary for Process Monitoring Assure desired product quality is being consistently manufactured Identify non-conforming material Supports Real Time Release (RTR) Evaluate the quality of final product based a combination of measured material attributes and process controls, ICH Q8 R(2) RTR facilitated by on-line measurements or surrogate assays (e.g. dissolution testing) Supports process development Continuous and fast response of process to factor changes allows efficient experimentation Increases process understanding within the range of conditions studied during development 6
7 7 In-Process Controls To assure batch uniformity in-process controls shall be established CFR (a) Examinations to be conducted on appropriate samples of in-process materials for each batch Requires higher frequency measurements for continuous processes compared to batch processes Controls shall monitor and validate the performance of the manufacturing processes that may cause variability in the drug product Valid in-process specifications shall be consistent with the release specification CFR (b) Limits shall be derived from acceptable process variability estimates where possible Rejected in-process materials shall be identified and isolated CFR (d) PAT tools can be utilized to meet the expectations for inprocess monitoring Establish that the process is consistently producing the desired quality Approaches may include multivariate process monitoring
8 Reliability/Quality Pyramid 8 Process Monitoring for the Prevention of Abnormal Events Abnormal Events: An operating situation occurring within a processing unit that could result in adverse consequences (out of spec product, equipment malfunction, process safety incident etc.)
9 9 Process Monitoring and Control Items to Assist Operator Monitoring and Control Activities Console Graphics Advanced Controls Process Monitoring Alarm System Shutdown Systems Process monitoring tools are an added layer of protection to help operations pro-actively intervene in the process and bridge the gap during the time between normal and alarm conditions
10 10 Approaches for Process Monitoring Statistical Quality Control (SQC) Variability in quality attributes of the product are monitored over time Statistical Process Control (SPC) The variability in critical process parameters and in-process quality measurements are monitored over time Monitoring the process variables expected to supply more information (e.g., detection and diagnosis) May generate a large number of univariate control chart that need to be monitored Multivariate Statistical Process Control (MSPC) Takes advantage of correlations between process variables Reduces the dimensionality of the process into a set of independent variables May detect abnormal operations not observed by SPC Operator Overview Display
11 Multivariate Statistical Process Monitoring Example Furnace Monitoring O Process Data is Highly Correlated T F T F T D F Advanced Process Control Objectives 1. Maintain outlet temperature at SP 2. Maximize throughput Process Monitoring Objectives 1. Detect Furnace Flooding 2. Multivariate Control Chart: Reduce Dimensionality/Enhance Fault Detection Out of Control Period Heat Balance Deviation 11
12 12 Multivariate Process Monitoring Methods Latent Variable Models Process data and product quality data are decomposed into new a set of independent variables Principal Component Analysis (PCA) Determines the latent variables that maximize the variation in process data captured by the model Well suited for process monitoring applications Partial Least Squares (PLS) Determines the latent variable that maximizes the correlation between the process and product quality data Well suited for predicting quality attributes from process data (e.g. soft sensors, surrogate models etc.) Model statistics can be calculated to assess the overall health of the process Hotelling T 2 : Able to detect process stretches SPEX: Able to detect a change in the relationship between process variables
13 13 Diagnosing Process Faults Hotelling T 2 The distance of the current operating point from the mean of the historical normal process data Squared Predicted Error Sum of the squared error between the model predicted and measured process variables
14 Considerations for the implementation of MSPC for continuous process Continuous manufacturing facilitates the adoption of MSPC for process monitoring Simplifies the model building process do not need account for changes in the process with respect to time There is generally an increase in the amount of process and quality data available for analysis Best practice considerations for the implementation of MSPC Variable selection for MSPC models Data selection for building MSPC models Variable transformations MSPC model validation On-line implementation 14
15 15 Variable Selection for MSPC Models Utilize process knowledge to select variables Risk assessment approaches may be used to identify failure modes Identify process variables that signal each failure mode Identify correlated process parameters Statistical approach used to identify process variables that are related Dependent upon the process data selected for analysis Investigate control variables as well as process variables Tightly controlled process variables typically provide little information Information may be contained in the manipulated variable (e.g., valve opening etc.) L The % valve opening contains information about the variation in the process
16 16 Data Selection for MSPC Model Building Historical data utilized should capture the normal variations expected during the process lifecycle Should include data from routine operations (e.g. feeder refills, etc.) Process data from disturbances should be removed from the model building data set Minimize amount of steady-state data included in the model building data set Steady state data masks the relationship between variables (variation is mostly due to noise) Statistic filters can be used to remove steady state data Majority of variation reflects noise Majority of variation reflects physical relationship
17 17 Data Selection Considerations Cont d Relationships between variables are influenced by the process design and the process control structure Control structure may not be finalized till the end of process development May impact the applicability of process development data for model building MSPC models may need to be re-vamped after process control projects are implemented MSPC models may be initially constructed from process performance qualification data Process qualification combines the actual facility, utilities, equipment with the commercial manufacturing process, control procedures, and components to the end product MSPC models may be updated as part continuous process verification Unlikely that all the sources of normal variation will be experienced during the process qualification process
18 18 Considerations for Variable Transformations Process data is typically auto-scaled prior to model building Mean-centered to focus on variation (i.e. x =0) Scaled by the standard deviation to equally weight each variable (i.e. s=1) The mean and std. dev. of each process variable is calculated from the model building data set A constant mean may not be suitable for monitoring a continuous process Filter mean to remove the impact of slow process shifts or a change in operating condition (e.g., high vs low flow rates) Filter constant should be based on the process time constant Increased sensitivity over a process run
19 19 Variable Transformations Cont d Weight variables to increase model sensitivity to failure modes based on prior knowledge and risk assessment Considering increasing the weight of variables that are early indicators of faults identified by the risk analysis Considering decreasing the weight of redundant measurements (e.g., multiple temperature measurements in an unit operation) PCA/PLS multivariate models are static and linear Utilize transformations to incorporate non-linear relationship Need to compensate for time lags in upstream and downstream process variables The MSPC models should utilize the dynamically compensated variable
20 20 MSPC Model Validation Utilize independent data sets for validation studies Validate models with normal operating data Goal is to minimize false positive alerts Validate models with operating data during process disturbances (if available) Assess detection ability and timing for process faults Set the model alert thresholds balancing the risk between missed events, false positives, and detection timing Better performance obtained by setting SPEX and T2 limits based on validation studies rather than the std. dev. obtained form normal operating data Minimizes false positives with minimal impact on detection capability or detection timing
21 21 On-line Implementation Considerations Ensure reading of process variables are synchronized Facilitated be integrating all process and quality data into a single source (e.g., process historian, supervisory control system, etc.) Ensure process data are not compressed Process historians may utilize compression for storing data Data compression can mask the relationship between process variables Need to account for missing and bad data May be able to use model estimates for the missing data Need to establish criteria when the status of the model will become bad (e.g., number of bad inputs, missing critical inputs) Utilize bumpless transfers when missing process data becomes available Incorporate MSPC model into the Quality Management System Establish work process for responding to alerts Establish work process for assessing the health of the MSPC model
22 22 Relationship between Real Time Release, Process Monitoring, and PAT Real-time-release (RTR), when used, is part of the Control Strategy Can include some or all of then finale product CQAs Not all Process Analytical Technology leads to RTR PAT systems can be designed to control CQAs of raw materials or inprocess materials and not contribute to RTR Some PAT tools may be utilized for both process monitoring and RTR MSPC approaches that establish a process signature are an evolving approach for RTR Science and risk based approaches generally required for MSPC to ensure that it monitors the relevant failure modes
23 23 Concluding Remarks Continuous manufacturing process facilitate the adoption of PAT tools for the development of process understanding, process monitoring, and real time release testing PAT may required to meet the regulatory requirements for in-process monitoring Process monitoring is a complementary control tool for the detection and diagnosis of deviations from normal operating conditions MSPC offers several advantages over univariate monitoring of process data MSPC approaches that establish a process signature are an evolving approach for RTR
PAT for the On-line Characterization of Continuous Manufacturing Systems
PAT for the On-line Characterization of Continuous Manufacturing Systems Thomas O Connor, Ph.D. Office of Pharmaceutical Science FDA/PQRI Conference: Innovation in Manufacturing and Regulatory Assessment
More informationScientific Considerations for Continuous Manufacturing Processes
Scientific Considerations for Continuous Manufacturing Processes Thomas O Connor, Ph.D. Science Staff Office of Pharmaceutical Quality 2nd FDA/PQRI Conference on Advancing Product Quality October 5th,
More informationBatch Statistical Process Control (BSPC): a powerful multi-level risk & process analytics tool
Batch Statistical Process Control (BSPC): a powerful multi-level risk & process analytics tool AgroStat 2016 March 21-24, 2016 Lausanne Sébastien Preys Ondalys France Consulting and Training in Chemometrics
More informationCurrent FDA Perspective for Continuous Manufacturing
Current FDA Perspective for Continuous Manufacturing Sau (Larry) Lee, Ph.D. Deputy Director (Acting) & Emerging Technology Team Chair Office of Testing and Research Office of Pharmaceutical Quality US
More informationNIRS, PAT, RTR testing EU experience and regulatory perspective
NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in
More informationRegulatory Perspective on Implementation of Multivariate Statistical Process Control for Pharmaceutical Manufacturing
Regulatory Perspective on Implementation of Multivariate Statistical Process Control for Pharmaceutical Manufacturing Biopharmaceutical Summit Lowell, MA, May 30, 2014, Bogdan Kurtyka, PhD. Review Chemist
More informationScientific and Regulatory Considerations for Continuous Manufacturing Implementation for Drug Product
Scientific and Regulatory Considerations for Continuous Manufacturing Implementation for Drug Product Arwa El Hagrasy, Ph.D. Quality Assessment Lead (Acting) Office of Process and Facilities OPQ/FDA PQRI
More informationScientific Considerations for Continuous API Manufacturing
Scientific Considerations for Continuous API Manufacturing Thomas O Connor, Ph.D. Office of Pharmaceutical Quality/Office of Testing and Research US FDA Center for Drug Evaluation and Research FDA PQRI
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. FDA Perspective on the Use of Process Capability
FDA Perspective on the Use of Process Capability Chunsheng Cai, Ph.D. Office of Process and Facilities Office of Pharmaceutical Quality, CDER, FDA 2017 ISPE Annual Meeting & Expo Disclaimer This presentation
More informationProcess Analyzer Continuous Verification
Process Analyzer Continuous Verification Jason E. Dickens, PhD Property of GlaxoSmithKline 2 PAT Cost-Complexity-Benefit Continuum Low End High End Simple Sensors Univariate Analyzers Spectral Analyzers
More informationAchieving Quality Beyond Compliance Through Continuous Manufacturing
Achieving Quality Beyond Compliance Through Continuous Manufacturing, Ph.D. Regional Head Quality Operation Novartis Pharma Disclaimer This presentation is based on publicly available information. These
More informationIntegrated Predictive Maintenance Platform Reduces Unscheduled Downtime and Improves Asset Utilization
November 2017 Integrated Predictive Maintenance Platform Reduces Unscheduled Downtime and Improves Asset Utilization Abstract Applied Materials, the innovator of the SmartFactory Rx suite of software products,
More informationContinuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation
Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation Christina Capacci-Daniel, Ph.D. Consumer Safety Officer / Acting Quality Assessment
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationContinuous Manufacturing
Continuous Manufacturing Continuous ing in the Industry Continuous processing has been adopted by the majority of process industries for the manufacturing of fluids (i.e. liquids and gasses) and solids
More informationPQLI Engineering Controls and Automation Strategy
J Pharm Innov (2008) 3:88 94 DOI 10.1007/s12247-008-9031-5 PRODUCT QUALITY LIFECYCLE IMPLEMENTATION (PQLI) INNOVATIONS PQLI Engineering Controls and Automation Strategy Ray Bolton Stephen Tyler Published
More informationImplementing Continuous Pharmaceutical Manufacturing: An FDA Perspective
Implementing Continuous Pharmaceutical Manufacturing: An FDA Perspective Christina Capacci-Daniel, Ph.D. Acting Quality Assessment Lead / Consumer Safety Officer Division of Inspectional Assessment, Office
More informationContinuous Manufacturing: An Industry View
Novartis Pharmaceuticals Continuous Manufacturing: An Industry View Diane Zezza Novartis Pharmaceuticals FDA/PQRI Conference on Advancing Product Quality March 22, 2017 Where are we today? Continuous Manufacturing
More informationFDA Perspective on Continuous Manufacturing
FDA Perspective on Continuous Manufacturing Sau (Larry) Lee, Ph.D. Director & Emerging Technology Team Chair Office of Testing and Research Office of Pharmaceutical Quality US FDA Center for Drug Evaluation
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationStrategic Implantation of PAT : FDA Perspective
Strategic Implantation of PAT : FDA Perspective Moheb M. Nasr, Ph.D. CDER, FDA MOHEB.NASR@FDA.HHS.GOV IFPAC 2008 Strategic Implantation of PAT Baltimore, MD January 27, 2008 Outline The Desired State -
More informationScientific and Regulatory Considerations for Implementing Mathematical Models in the Quality by Design (QbD) Framework
Online Exclusive from PHARMACEUTICAL ENGINEERING THE OFFICIAL TECHNICAL MAGAZINE OF ISPE NOVEMBER/DECEMBER 2014, VOL 34, NO 6 Copyright ISPE 2014 www.pharmaceuticalengineering.org regulatory compliance
More informationCONSIDERATIONS OF CONTINUOUS MANUFACTURING PROCESSES
LCDR Patric Klotzbuecher U.S. FDA/Office of Regulatory Affairs/New York District 3 rd FDA/PQRI Conference on Advancing Product Quality March 22 24, 2017 CGMP AND REGULATORY CONSIDERATIONS OF CONTINUOUS
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationSiemens AG All rights reserved.
How to create a PAT data management platform to support Continuous Production 8th Annual PAT and QbD Conference, London, February 16 th, 2011 Jan Verelst Back in time Page 2 What caused this disaster?
More informationQuality by Design Considerations for Analytical Procedures and Process Control
Quality by Design Considerations for Analytical Procedures and Process Control Moheb M. Nasr, Ph.D. ONDQA/CDER/FDA IFPAC 2009 Baltimore, MD January 26, 2009 1 Outline Background on FDA Initiatives and
More informationPharmaceutical control strategy what does it mean and how do we apply? Martin Warman, Martin Warman Consultancy Ltd
Pharmaceutical control strategy what does it mean and how do we apply? Martin Warman, Martin Warman Consultancy Ltd How can the words control strategy cause such debate? Means totally different things
More informationA Framework and Case Study for Implementing the New Process Validation Guidance
A Framework and Case Study for Implementing the New Process Validation Guidance Presented By Bikash Chatterjee President and Chief Technology Officer Pharmatech Associates Agenda Introduction Comparing
More informationPMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft)
PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft) March 30, 2018 Pharmaceuticals and Medical Devices Agency Innovative Manufacturing Technology
More informationQuality by Design (QbD)
Evaluating the Critical Quality attributes & Critical Process Parameters-A Case Study-Tablets GMP International Workshop February 20/21, 2008 Mumbai, India Mukund Yelvigi Director, Therapeutic Area Management,
More informationQuality by Design, Revolution or Evolution? Wim Oostra
Quality by Design, Revolution or Evolution? Wim Oostra 1993 1998 2007 2009 2013 And many more.. Content Introduction A bit of history Examples A New product Legacy product Today? The triggers The goal
More informationStage 3 - Process Validation: Measuring what matters
Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company
More informationCHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE
CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14
More informationAchieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics
Achieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics By Fernando Muzzio, Marianthi Ierapetritou, Rohit Ramachandran, Amanda
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationFault tolerant control for safe plant operation. November 10, 2016
Real Time Release in Continuous Solid Dose Manufacturing: Systematic Characterization of Material Properties, and Optimal Design of Sensing and Control Methods Fault tolerant control for safe plant operation
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationInnovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series
CAMO European Pharmaceutical Seminars Jan/Feb 2009 Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series The Increasing Need of Multivariate Analysis for Process Understanding
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationCurrent Industry Practices in Manufacturing Process Validation. Russ Somma PhD
Russ Somma PhD The objectives for validation are: Demonstrate control over the process and finished product. Demonstrate that the process will consistently produce product which meets all specifications
More informationAssociation. Case Study 3. achieving real time release testing by a
Case Study 3 Applying PDA: QbD for A a legacy Global product and achieving real time release testing by a design Association space approach with supportive PAT and soft sensor based models: Challenges
More informationThe new BioPAT MFCS 4
The new BioPAT MFCS 4 Developed for the Process Designed for You! turning science into solutions Page 1 Contents 1 Overview 2 3 4 Features & Highlights Good to know Outlook Page 2 Overview BioPAT MFCS
More informationA COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION
A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX
More informationImplementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork
Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering
More informationcgmp and Regulatory Considerations of Continuous Manufacturing Processes
cgmp and Regulatory Considerations of Continuous Manufacturing Processes LCDR Patric Klotzbuecher U.S. FDA/Office of Regulatory Affairs/New York District 2 nd FDA/PQRI Conference on Advancing Product Quality
More informationApproval Application Form for Sakura Bloom Tablets
Approval Application Form for Sakura Bloom Tablets Mock-up for Columns of Manufacturing Methods and Specifications & Test Methods for Drug Products (sample description) Study project for regulatory harmonization
More informationThe Emerging Technology Program: FDA s Perspective
The Emerging Technology Program: FDA s Perspective Mohan Sapru, M.S., Ph.D. Member Emerging Technology Team (ETT) CMC Lead Application Technical Lead Office of New Drug Products Office of Pharmaceutical
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationStatistics and Pharmaceutical Quality
Statistics and Pharmaceutical Quality Karthik Iyer (CQE, CSSBB) Senior Policy Advisor CDER/OC/OMPQ January 24 th, 2014 IFPAC * This presentation reflects the views of the author and should not be construed
More informationApplication of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013
Application of PAT for Tablet Analysis Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013 Agenda PAT@Novartis Organization Business Drivers and Cases NIR Spectroscopy for
More informationPROCESS VALIDATION ANSM 2015 FDA 2011
PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationBatch Process Analysis using MPCA/MPLS, A Comparison Study
Batch Process Analysis using MPCA/MPLS, A Comparison Study Salvador Garcia Dept. of Chemical Engineering, McMaster University, Hamilton, Ontario, L8S 4L7, Canada Abstract Batch processes can be monitored
More informationEnhancing Product Quality through CM An Industry Perspective for Transitioning CM from Technology Evaluation to a Default Manufacturing Platform
Enhancing Product Quality through CM An Industry Perspective for Transitioning CM from Technology Evaluation to a Default Manufacturing Platform Ahmad Almaya Lilly Research Laboratories Eli Lilly and Company
More informationAn integrated multi-layer approach to control strategy for continuous drug product manufacture
An integrated multi-layer approach to control strategy for continuous drug product manufacture Ahmad Almaya, Ph.D. Eli Lilly and Company February 2016 Lilly s Journey with DP CM 2010 Business Case 2011
More informationContributed to AIChE 2006 Annual Meeting, San Francisco, CA. With the rapid growth of biotechnology and the PAT (Process Analytical Technology)
Bio-reactor monitoring with multiway-pca and Model Based-PCA Yang Zhang and Thomas F. Edgar Department of Chemical Engineering University of Texas at Austin, TX 78712 Contributed to AIChE 2006 Annual Meeting,
More informationIdentifying and Controlling CPPs and CMAs
March 2018, BioPharm International Publication Identifying and Controlling CPPs and CMAs Thomas A. Little Ph.D. 2/22/2018 President/CEO Thomas A. Little Consulting, BioAssay Sciences 12401 N Wildflower
More informationApplied Process Understanding in Drug Product Development
Applied Process Understanding in Drug Product Development A combined pharmaceutical science, materials science and chemical process engineering approach 17 October, Heidelberg, Germany ir Sander van den
More informationSeptember 21, Dear Sir or Madam:
September 21, 2017 US Food and Drug Administration Division of Dockets Management (HFA-305) 5630 Fishers Lane, Rm 1061 Rockville, Maryland 20852 via electronic submission Subject: Docket No. FDA-2017-N-2697
More informationMASTER PLANNING FOR VALIDATION
MASTER PLANNING FOR VALIDATION By: Gamal Amer, Ph.D. Principal, Premier Compliance Services, Inc. 1 Process Validation: General Principles and Practices Guidance to industry issued by the FDA in January
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationBMS Experience with the FDA-EMA QbD/PAT Joint Pilot Ambarish K. Singh, PhD Director, Global Regulatory Sciences-CMC Bristol-Myers Squibb Company
BMS Experience with the FDA-EMA QbD/PAT Joint Pilot Ambarish K. Singh, PhD Director, Global Regulatory Sciences-CMC Bristol-Myers Squibb Company FDA/PQRI Conference on Evolving Product Quality September
More informationINTRODUCTION. Received on: 07/03/2017 Revised on: 05/07/2017 Accepted on: 11/11/2017
Review Article Real Time Release Testing-A Review Gayathri Devi N. R*, Chandramouli R Department of Quaity Assurance, Krupanidhi College of Pharmacy Bangalore, Karnataka, India 10.18579/jpcrkc/2017/16/4/111489
More informationPAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany
PAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany ir Sander van den Ban, CEng The Unpredictability of
More informationManufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space
Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies Case Study Title: Defining Process Design Space Case No. RMWG-07 GMP System Impacted: Introduction / Background
More informationQuality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June
More informationSTATISTICAL PROCESS MONITORING OF BIOREACTORS: A COMPARISON
STATISTICAL PROCESS MONITORING OF BIOREACTORS: A COMPARISON Wu Long, Ognjen Marjanovic, Barry Lennox Control Systems Centre, School of Electrical and Electronic Engineering, University of Manchester, United
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationMatching Flows: The Development of Continuous Manufacturing of Biotech Products
Matching Flows: The Development of Continuous Manufacturing of Biotech Products Jeffrey C. Baker, Ph.D. Deputy Director, Office of Biotechnology Products, CDER By telecon to ECI s Integrated Continuous
More informationQuality by Design Facilitating Real Time Release (RTR) Practical Challenges and Opportunities during RTR Implementation
Quality by Design Facilitating Real Time Release (RTR) Practical Challenges and Opportunities during RTR Implementation Carl E. Longfellow Ph.D., Senior Director, New Product and Process Development, Discussion
More informationInt. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries
Review Article Process Validation of Tablet Dosage Form in Industries Ram Mohan S.R, N. Vishal Gupta* Pharmaceutical Quality Assurance group, Dept of Pharmaceutics, JSS University, Sri ShivarathreeshwaraNagara,
More informationApplying QbD and Pat in Biological Manufacturing for Continued Process Verification
University of Rhode Island DigitalCommons@URI Open Access Dissertations 2013 Applying QbD and Pat in Biological Manufacturing for Continued Process Verification Prakash Bedre University of Rhode Island,
More informationNovartis E2E CM case study
Technical R&D/CHAD CM Unit Novartis E2E CM case study Markus Krumme, CM Unit Head Cambridge, MA September 26, 2016 Continuous Manufacturing at Novartis Basel ~300 m 2 productive area, 2 upstream trains,
More informationProcess Design Risk Management A Proactive Approach
Page 1 of 7 Guest Column August 30, 2017 Process Design & Risk Management A Proactive Approach By Sandra Wassink, Principal Process Engineer, Pharmatech Associates The FDA has given us the green light
More informationPRODUCTION AND PERFORMANCE MANAGEMENT DATA HISTORIANS FOR INCIDENT AND DEVIATION MANAGEMENT IN THE REGULATED INDUSTRIES
PRODUCTION AND PERFORMANCE MANAGEMENT DATA HISTORIANS FOR INCIDENT AND DEVIATION MANAGEMENT IN THE REGULATED INDUSTRIES DATA HISTORIANS FOR INCIDENT AND DEVIATION MANAGEMENT DATA HISTORIANS FOR INCIDENT
More informationThe Role of Quality Risk Management in New Drug Development and Manufacturing
The Role of Quality Risk Management in New Drug Development and Manufacturing CASSS CMC Strategy Forum Bethesda, MD July 27, 2009 Terrance Ocheltree, RPh, PhD Pharmaceutical Assessment Lead (Acting) Office
More informationValue from Data - Applying MVDA for real-time monitoring, prediction & control
Value from Data - Applying MVDA for real-time monitoring, prediction & control Presented by Petter Moree Umetrics Domenic Schimizzi Genentech OSIsoft PI System with SIMCA-online in the Pilot Plant Access
More informationLifecycle of NIR Analytical Methods: Regulatory Perspective
Lifecycle of NIR Analytical Methods: Regulatory Perspective Bogdan Kurtyka, Ph.D. FDA/OPQ/OPF IFPAC Annual Meeting January 27, 2015 Outline Method lifecycle Impact of selected elements of lifecycle on
More informationGuidance for Industry
Guidance for Industry ANDAs: Blend Uniformity Analysis DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationOverview of Statistics used in QbD Throughout the Product Lifecycle
Overview of Statistics used in QbD Throughout the Product Lifecycle August 2014 The Windshire Group, LLC Comprehensive CMC Consulting Presentation format and purpose Method name What it is used for and/or
More informationPAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets. Part 1: Concept and Principles Part 2: Mock P2 Submission
PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets Part 1: Concept and Principles Part 2: Mock P2 Submission 1 Part 1 Concept and Principles Introduction Rationale Concept
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationOmron meets Pharma Milan, January 29 th Container Closure Integrity Testing (CCIT): a Risk Management Application
Omron meets Pharma Milan, January 29 th 2014 Container Closure Integrity Testing (CCIT): a Risk Management Application Marco Silvestri Andrea Simonetti Process: Container Closure Integrity Testing for
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationDaniel Y. Peng, Ph.D.
Using Control Charts to Evaluate Process Variability Daniel Y. Peng, Ph.D. Quality Assessment Lead Office of Process and Facility (OPF) OPQ/CDER/FDA PQRI 205 Annual Meeting North Bethesda, Maryland October
More information3 Steps to Better Steam Temperature Control Proven Strategies to Minimize Thermal Stress and Tube Leaks
December 17 3 Steps to Better Proven Strategies to Minimize Thermal Stress and Tube Leaks www.emerson.com/ December 17 Commercial power generators are having to significantly change how they operate their
More informationLatino America Consultores Innovation & Technology to make your Business Compliant
Latino America Consultores Innovation & Technology to make your Business Compliant Annex 15 & EMA Process Validation Guide Line 1 Changes in Requirements The Pharmaceutical Industry has adapted its business
More informationScientific and Regulatory challenges in Quality by Design (QbD) submissions
Health Santé Canada Canada Scientific and Regulatory challenges in Quality by Design (QbD) submissions Krishnan R. Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences TPD, Health Canada CVG, October 2007
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationMaking APC Perform 2006 ExperTune, Inc. George Buckbee, P.E. ExperTune, Inc.
Making APC Perform 2006 ExperTune, Inc. George Buckbee, P.E. ExperTune, Inc. Summary Advanced Process Control (APC) promises to deliver optimal plant performance by optimizing setpoints, decoupling interactions,
More informationUnderstanding and accounting for product
Understanding and Modeling Product and Process Variation Variation understanding and modeling is a core component of modern drug development. Understanding and accounting for product and process variation
More informationPQLI Control Strategy Model and Concepts
J Pharm Innov (008) :95 104 DOI 10.1007/s147-008-905-1 PRODUCT QUALITY LIFECYCLE IMPLEMENTATION (PQLI) INNOVATIONS PQLI Control Strategy Model and Concepts Bruce Davis Line Lundsberg Graham Cook Published
More informationTraditional Validation - Downstream
EMA Expert Workshop on Validation of Manufacturing for Biological Medicinal Products Tuesday 9 th April 2013 Traditional Validation - Downstream Norbert Hentschel Content of the Presentation 5. Should
More informationQuality by Design for Drug Products. Dr. Lorenz Liesum Global Technical Operation, Novartis Swiss Association for Quality Meeting , Olten
Quality by Design for Drug Products Dr. Lorenz Liesum Global Technical Operation, Novartis Swiss Association for Quality Meeting 04-03-2010, Olten Overview QbD/PAT Concept QbD/PAT Toolbox DoEs PAT Methods
More informationStatistics in Validation. Tara Scherder CSO Supply, Arlenda, Inc
Statistics in Validation 05 Arlenda Tara Scherder CSO Supply, Arlenda, Inc IVT Validation Week Philadelphia, PA Oct 7,05 Agenda Evolution of Validation 0 FDA Guidance Why Use Statistics Stage Process Design
More informationDissolution and clinically relevant specifications: linking clinical performance to dissolution
Dissolution and clinically relevant specifications: linking clinical performance to dissolution Talia Flanagan, Dave Holt, Paul Dickinson, Paul Stott. FDA/PQRI Conference on Evolving Product Quality 16-17
More informationPlantTriage Project Execution at Ammonia Plant
Contents Background... 2 Project Initiation... 2 Project Methodology... 3 Project Results... 4 Project Results Documentation... 5 1. Process Response Testing and Controller Tuning... 5 Example1 Primary
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015
Ref. Ares(2015)3808922-15/09/2015 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, [date] This document is for consultation until 11
More information